ONINTZA
SAGREDO EZQUIOGA
Profesora titular de universidad
Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas
Madrid, EspañaPublications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (17)
2023
-
Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome
Neuropharmacology, Vol. 237
-
Retinal Tissue Shows Glial Changes in a Dravet Syndrome Knock-in Mouse Model
International Journal of Molecular Sciences, Vol. 24, Núm. 3
2022
-
Editorial: Cannabinoids as potential treatment for neurological diseases
Frontiers in Neuroscience
-
Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome
Neuropharmacology, Vol. 205
2021
-
Chapter 2: Phytocannabinoids Versus Endocannabinoids. A Modern View of the Endocannabinoid System
RSC Drug Discovery Series (Royal Society of Chemistry), pp. 10-47
-
Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments
Frontiers in Molecular Neuroscience, Vol. 13
2020
-
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
European Neuropsychopharmacology, Vol. 36, pp. 217-234
2018
-
Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders
Biochemical Pharmacology, Vol. 157, pp. 85-96
2017
-
Effects of a sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of huntington’s disease
International Journal of Molecular Sciences, Vol. 18, Núm. 4
2016
-
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease
Journal of Neurology, Vol. 263, Núm. 7, pp. 1390-1400
-
Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome
Pharmacology Research and Perspectives, Vol. 4, Núm. 2
2013
-
Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?
British Journal of Clinical Pharmacology, Vol. 75, Núm. 2, pp. 323-333
-
Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy
Journal of Alzheimer's Disease, Vol. 35, Núm. 3, pp. 525-539
-
The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: A potential role of cyclooxygenase-2-dependent metabolism of 2-AG
Cell Death and Disease, Vol. 4, Núm. 10
2012
-
Cannabinoids: Novel medicines for the treatment of Huntington's disease
Recent Patents on CNS Drug Discovery, Vol. 7, Núm. 1, pp. 41-48
2009
-
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Brain, Vol. 132, Núm. 11, pp. 3152-3164
2007
-
Cannabinoids and neuroprotection in Basal ganglia disorders
Molecular Neurobiology, Vol. 36, Núm. 1, pp. 82-91